LFM-A13

Modify Date: 2024-01-20 23:48:03

LFM-A13 structure	Common Name	LFM-A13
	CAS Number	62004-35-7	Molecular Weight	360.00
	Density	1.9±0.1 g/cm3	Boiling Point	487.9±45.0 °C at 760 mmHg
	Molecular Formula	C₁₁H₈Br₂N₂O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	248.9±28.7 °C

Use of LFM-A13

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

Name	LFM-A13,2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
Synonym	More Synonyms

Description	LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Signaling Pathways >> Cell Cycle/DNA Damage >> Polo-like Kinase (PLK) Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Btk
Target	Plx1:10 μM (IC50) PLK3:61 μM (IC50) BRK:267 μM (IC50) BMX:281 μM (IC50) FYN:240 μM (IC50) Met:215 μM (IC50) Btk:2.5 μM (IC50)
References	[1]. Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99. [2]. van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13. [3]. Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14. [4]. Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2018 Jun;36(3):388-395.

Density	1.9±0.1 g/cm3
Boiling Point	487.9±45.0 °C at 760 mmHg
Molecular Formula	C₁₁H₈Br₂N₂O₂
Molecular Weight	360.00
Flash Point	248.9±28.7 °C
Exact Mass	357.895233
PSA	73.12000
LogP	3.42
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.677

Hazard Codes	Xn
Risk Phrases	20/21/22
Safety Phrases	36/37

2-Butenamide, 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-, (2Z)-

a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide

(2Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide

trans-4,5-didehydro-neral

dehydrocitral

trans-dehydroneral

2,4,6-Octatrienal,3,7-dimethyl

(2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide

LFM-A13

Use of LFM-A13

Names

LFM-A13 Biological Activity

Chemical & Physical Properties

Safety Information

Synonyms